{
    "clinical_study": {
        "@rank": "117504", 
        "arm_group": {
            "arm_group_label": "prucalopride", 
            "arm_group_type": "Active Comparator", 
            "description": "0.01 mg/kg/day to 0.03 mg/kg/day prucalopride (R108512) oral solution"
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is characterize the efficacy, safety, tolerability, and\n      steady-state plasma levels after once-daily oral dosing of prucalopride (R108512) as a\n      solution, 0.01 mg/kg to 0.03 mg/kg, given to paediatric subjects with functional faecal\n      retention (FFR)  for 8 weeks.\n\n      Hypothesis:\n\n      Pharmacokinetic profile of prucalopride in paediatric subjects is expected to resemble the\n      adult pharmacokinetic profile. Safety and tolerability profile are expected to resemble the\n      adult profile."
        }, 
        "brief_title": "Prucalopride in Paediatric Subjects, With Functional Faecal Retention", 
        "completion_date": {
            "#text": "July 1999", 
            "@type": "Actual"
        }, 
        "condition": "Constipation", 
        "condition_browse": {
            "mesh_term": "Constipation"
        }, 
        "detailed_description": {
            "textblock": "This is a multicentre, open-label trial in which paediatric subjects (ages 4 to 12 years)\n      with FFR were administered prucalopride in oral solution once daily for 8 weeks. Subjects\n      who entered this extension trial had completed PRU-USA-12, a single-dose pharmacokinetic\n      trial, usually within the previous week.\n\n      Evaluations for efficacy, safety and tolerability were performed, and plasma samples for\n      analysis of prucalopride levels were obtained at 2, 4, 6 and 8 weeks.\n\n      The initial dosage of prucalopride oral solution was 0.02 mg/kg/day. Dependent on the\n      subject's response, the parent could adjust the dosage within a range of 0.01 mg/kg/day to\n      0.03 mg/kg/day."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Subject completed the PRU-USA-12 pharmacokinetic trial\n\n          -  Subject bowels had been \"cleaned-out\" (ie, any faecal impactions removed)\n\n          -  Written informed consent, signed by the subject's legal guardian and by the\n             investigator\n\n          -  Subject assent documented in the form of a note-to-file in the subject's source\n             documentation\n\n        Exclusion Criteria:\n\n        \u2022 No exclusion criteria"
            }, 
            "gender": "Both", 
            "maximum_age": "12 Years", 
            "minimum_age": "4 Years"
        }, 
        "enrollment": {
            "#text": "37", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "July 31, 2012", 
        "id_info": {
            "nct_id": "NCT01670669", 
            "org_study_id": "PRU-USA-24"
        }, 
        "intervention": {
            "arm_group_label": "prucalopride", 
            "description": "0.01 mg/kg/day to 0.03 mg/kg/day prucalopride (R108512) oral solution", 
            "intervention_name": "prucalopride", 
            "intervention_type": "Drug"
        }, 
        "lastchanged_date": "August 20, 2012", 
        "number_of_arms": "1", 
        "official_title": "An Open-label Follow-up Study of 0.01 mg/kg/Day to 0.03 mg/kg/Day Prucalopride (R108512) Oral Solution in Paediatric Subjects, Aged >= 4 to <= 12 Years With Functional Faecal Retention (FFR), Who Participated in the PRU-USA-12.", 
        "overall_official": {
            "affiliation": "Massachusetts General Hospital for Children, Boston, Massachusetts, USA", 
            "last_name": "Harald Winter, M.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "July 1999", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "description": "Adverse events (AEs) to be recorded by spontanous reporting or after non-leading questioning i.e. reporting of all AEs and its duration during the course of the trial. In addition at bi-weekly visits laboratory assessments, vitals signs, ECGs and physical examinations, reported as mean values and clinical significant abnormalities to be tabulated.\nEfficacy: reporting of bowel movements and its characteristics in a diary.", 
                "measure": "Adverse events", 
                "safety_issue": "No"
            }, 
            {
                "description": "Reporting of bowel movement frequency, i.e. average number of bowel movements on a weekly base.", 
                "measure": "Efficacy", 
                "safety_issue": "No"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01670669"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Secondary efficacy variables: steady-state plasma levels after once-daily oral dosing of prucalopride (R108512) as a solution, 0.01 mg/kg to 0.03 mg/kg, given to paediatric subjects with functional faecal retention (FFR)  for 8 weeks.", 
            "safety_issue": "No", 
            "time_frame": "8 weeks"
        }, 
        "source": "Movetis", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Movetis", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 1998", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "August 2012"
    }
}